Cover Image
Market Research Report - 248823

Partnerships, Licensing, Investments and M&A Deals and Trends for November 2015 in Pharmaceuticals

Published by GlobalData
Published Content info 105 Pages
Price
Back to Top
Partnerships, Licensing, Investments and M&A Deals and Trends for November 2015 in Pharmaceuticals
Published: December 10, 2015 Content info: 105 Pages
Description

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for November 2015 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in November 2015. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the six months.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
Table of Contents

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Pharmaceuticals & Healthcare, Global, Deal Summary

  • 2.1. Pharmaceuticals & Healthcare, Global, Deal Analysis, November 2015
  • 2.2. Pharmaceuticals & Healthcare, Global, Major Deals, November 2015
    • 2.2.1. Allergan and Pfizer to Combine in USD160 Billion Deal
    • 2.2.2. Shire to Acquire Dyax
    • 2.2.3. AstraZeneca Prices Public Offering of Notes for USD6 Billion
    • 2.2.4. Sanofi to Enter into Licensing Agreement with Hanmi Pharma
    • 2.2.5. Teva Pharma Prices Public Offering of ADS for USD3.38 Billion
  • 2.3. Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, November 2015
  • 2.4. Pharmaceuticals & Healthcare, Global, by Type, Deal Values, November 2015

3. Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type

  • 3.1. Pharmaceuticals & Healthcare, Global, M&A, November 2015
    • 3.1.1. Top M&A Deals in November 2015
    • 3.1.2. Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, June 2015-November 2015
  • 3.2. Pharmaceuticals & Healthcare, Global, Equity Offering Deals, November 2015
    • 3.2.1. Top Equity Offering Deals in November 2015
    • 3.2.2. Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, June 2015-November 2015
  • 3.3. Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, November 2015
    • 3.3.1. Top PE/VC Deals in November 2015
    • 3.3.2. Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, November 2015
    • 3.3.3. Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, November 2015
    • 3.3.4. Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, June 2015-November 2015
    • 3.3.5. Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, June 2015-November 2015

4. Pharmaceuticals & Healthcare, Global, Partnership Deals, November 2015

  • 4.1. Pharmaceuticals & Healthcare, Global, Partnership Deals, November 2015
  • 4.2. Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, June 2015-November 2015
  • 4.3. Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), November 2015
    • 4.3.1. Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, November 2015
  • 4.4. Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), June 2015-November 2015
  • 4.5. Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, June 2015-November 2015
  • 4.6. Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), June 2015-November 2015
  • 4.7. Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), June 2015-November 2015

5. Pharmaceuticals & Healthcare, Global, Licensing Agreements, November 2015

  • 5.1. Pharmaceuticals & Healthcare, Global, Licensing Agreements, November 2015
  • 5.2. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2015
  • 5.3. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), June 2015-November 2015
  • 5.4. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), June 2015-November 2015
  • 5.5. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), June 2015-November 2015
  • 5.6. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), June 2015-November 2015
    • 5.6.1. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, November 2015
    • 5.6.2. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, November 2015
    • 5.6.3. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, November 2015

6. Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area

  • 6.1. Pharmaceuticals & Healthcare, Global, Oncology Deals, November 2015
    • 6.1.1. Oncology-Deals of the Month
  • 6.2. Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, November 2015
    • 6.2.1. Central Nervous System-Deals of the Month
  • 6.3. Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, November 2015
    • 6.3.1. Infectious Diseases-Deals of the Month
  • 6.4. Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, November 2015
    • 6.4.1. Cardiovascular-Deals of the Month
  • 6.5. Pharmaceuticals & Healthcare, Global, Immunology Deals, November 2015
    • 6.5.1. Immunology-Deals of the Month
  • 6.6. Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, November 2015
    • 6.6.1. Gastrointestinal-Deals of the Month
  • 6.7. Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, November 2015
    • 6.7.1. Metabolic Disorders-Deal of the Month

7. Deal Summary by Geography

  • 7.1. Pharmaceuticals & Healthcare, North America Deals, November 2015
    • 7.1.1. North America-Deals of the Month
  • 7.2. Pharmaceuticals & Healthcare, Europe, Deals, November 2015
    • 7.2.1. Europe-Deals of the Month
  • 7.3. Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, November 2015
    • 7.3.1. Asia-Pacific-Deals of the Month
  • 7.4. Pharmaceuticals & Healthcare, Rest of the World, Deals, November 2015
    • 7.4.1. Rest of the World-Deals of the Month

8. Pharmaceuticals & Healthcare, Global, Top Financial Advisors

  • 8.1. Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, June 2015-November 2015
  • 8.2. Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, June 2015-November 2015

9. Further Information

  • 9.1. Methodology
  • 9.2. About GlobalData
  • 9.3. Disclosure information
  • 9.4. Disclaimer

List of Tables

  • Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, November 2015
  • Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), November 2015
  • Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, November 2015
  • Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, June 2015 - November 2015
  • Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, November 2015
  • Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, November 2015
  • Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, June 2015 - November 2015
  • Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), November 2015
  • Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, June 2015 - November 2015
  • Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), June 2015 - November 2015
  • Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), November 2015
  • Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), June 2015 - November 2015
  • Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, June 2015 - November 2015
  • Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), June 2015 - November 2015
  • Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), June 2015 - November 2015
  • Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), November 2015
  • Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, June 2015 - November 2015
  • Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), November 2015
  • Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, November 2015
  • Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, November 2015
  • Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, November 2015
  • Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), June 2015 - November 2015

List of Figures

  • Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), November 2015
  • Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), November 2015
  • Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, June 2015 - November 2015
  • Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, June 2015 - November 2015
  • Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), November 2015
  • Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), November 2015
  • Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), June 2015 - November 2015
  • Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), June 2015 - November 2015
  • Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, June 2015 - November 2015
  • Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, June 2015 - November 2015
  • Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), June 2015 - November 2015
  • Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), June 2015 - November 2015
  • Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), June 2015 - November 2015
  • Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, June 2015 - November 2015
  • Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), June 2015 - November 2015
  • Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), November 2015
  • Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
  • Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), June 2015 - November 2015
Back to Top